top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Savara, Inc. - Common Stock (NQ:SVRA)

5.280 -0.050 (-0.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,259,498
Open 5.340
Bid (Size) 5.120 (5,000)
Ask (Size) 5.280 (100)
Prev. Close 5.330
Today's Range 5.180 - 5.400
52wk Range 2.430 - 7.005
Shares Outstanding 114,066,080
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline ↗
This clinical-stage biotech focused on rare lung diseases reported significant insider selling amid a year of strong share gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire

Performance

YTD
-6.4%
-6.4%
1 Month
-12.4%
-12.4%
3 Month
+8.9%
+8.9%
6 Month
-5.9%
-5.9%
1 Year
+101.5%
+101.5%

More News

Read More
News headline image
Savara Announces Chief Financial and Administrative Officer Transition
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
From Savara Inc.
Via Business Wire
News headline image
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
Via The Motley Fool
News headline image
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
From Savara Inc.
Via Business Wire
News headline image
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Reports First Quarter Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
From Savara Inc.
Via Business Wire
News headline image
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
News headline image
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in 2026 Citizens Life Sciences Conference
From Savara Inc.
Via Business Wire
News headline image
SVRA Stock Rises After Hours As FDA Grants Priority Review For Lung Disorder Therapy ↗
Via Stocktwits
Topics Intellectual Property Lawsuit
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
News headline image
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in Upcoming Investor Healthcare Conferences
From Savara Inc.
Via Business Wire

Frequently Asked Questions

Is Savara, Inc. - Common Stock publicly traded?
Yes, Savara, Inc. - Common Stock is publicly traded.
What exchange does Savara, Inc. - Common Stock trade on?
Savara, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Savara, Inc. - Common Stock?
The ticker symbol for Savara, Inc. - Common Stock is SVRA on the Nasdaq Stock Market
What is the current price of Savara, Inc. - Common Stock?
The current price of Savara, Inc. - Common Stock is 5.280
When was Savara, Inc. - Common Stock last traded?
The last trade of Savara, Inc. - Common Stock was at 07/29/26 04:00 PM ET
What is the market capitalization of Savara, Inc. - Common Stock?
The market capitalization of Savara, Inc. - Common Stock is 602.27M
How many shares of Savara, Inc. - Common Stock are outstanding?
Savara, Inc. - Common Stock has 602M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page